CTKB icon

Cytek Biosciences

2.57 USD
+0.15
6.20%
At close May 27, 4:00 PM EDT
After hours
2.57
+0.00
0.00%
1 day
6.20%
5 days
1.18%
1 month
-33.42%
3 months
-46.57%
6 months
-60.46%
Year to date
-60.88%
1 year
-56.66%
5 years
-86.30%
10 years
-86.30%
 

About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Employees: 663

0
Funds holding %
of 7,258 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

41% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 22

5% more funds holding

Funds holding: 151 [Q4 2024] → 159 (+8) [Q1 2025]

0.51% more ownership

Funds ownership: 59.95% [Q4 2024] → 60.47% (+0.51%) [Q1 2025]

21% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 63

38% less capital invested

Capital invested by funds: $501M [Q4 2024] → $311M (-$191M) [Q1 2025]

91% less call options, than puts

Call options by funds: $2K | Put options by funds: $22K

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
17%
upside
Avg. target
$5.67
120%
upside
High target
$8
211%
upside

3 analyst ratings

positive
67%
neutral
0%
negative
33%
Goldman Sachs
Matthew Sykes
17%upside
$3
Sell
Maintained
12 May 2025
Stephens & Co.
Mason Carrico
133%upside
$6
Overweight
Reiterated
19 Mar 2025
Piper Sandler
David Westenberg
211%upside
$8
Overweight
Maintained
4 Mar 2025

Financial journalist opinion

Based on 6 articles about CTKB published over the past 30 days

Neutral
Seeking Alpha
2 weeks ago
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call.
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
2 weeks ago
Cytek Biosciences Reports First Quarter 2025 Financial Results
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025.
Cytek Biosciences Reports First Quarter 2025 Financial Results
Positive
Seeking Alpha
3 weeks ago
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?
The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in 2024, its operating expenses represented 65.67% of its sales. In 2024, the company reported cash and cash equivalents and marketable securities of $277.86 million. Meanwhile, its total liabilities were $103.76 million in that year.
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?
Neutral
GlobeNewsWire
4 weeks ago
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Cytek Biosciences is showcasing its patented Full Spectrum Profiling™ technology at CYTO 2025 & American Association of Immunologists' (AAI) IMMUNOLOGY2025
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025
Positive
Seeking Alpha
4 weeks ago
Why Cytek Biosciences Should Beat Q1 Earnings Expectations
There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future growth prospects.
Why Cytek Biosciences Should Beat Q1 Earnings Expectations
Neutral
GlobeNewsWire
1 month ago
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
Neutral
GlobeNewsWire
2 months ago
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer, creating a next-generation instrument called the Cytek® Muse® Micro.
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System
Neutral
Seeking Alpha
2 months ago
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today.
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript
Positive
Zacks Investment Research
2 months ago
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates
Charts implemented using Lightweight Charts™